Last Modified: December 11, 2023

Daniel Nigh is a founding partner of the Washington D.C. law firm Nigh Goldenberg Raso & Vaughn. He specializes in a broad range of litigation types, including pharmaceutical litigation, medical device litigation, cryptocurrency exchange bankruptcies and mass torts.

His experience and dedication have led judges to appoint Nigh to several leadership positions in complex mass tort litigations.

Most recently, he became co-lead counsel for the valsartan multidistrict litigation, MDL 2875, centralized in New Jersey. He also oversees the science and experts committee as well as the bellwether committee. Nigh is also on the Plaintiffs Steering Committee for the Zantac MDL in Florida. The Court appointed him to chair the Zantac science and experts committee.

Before he was appointed to leadership positions in the valsartan and Zantac MDLs, Nigh helped start the Benicar drug litigation by co-filing the first Benicar lawsuit and chairing the discovery committee. Ultimately, he helped obtain a $358 million global settlement.

His experience in defective medical device litigation includes playing leadership roles in the DePuy ASR, Bair Hugger and transvaginal mesh litigations. He also played key roles in working on settlements for the DePuy Attune and DePuy Pinnacle hip litigations.

Nigh graduated magna cum laude from Stetson Law School in Gulfport, Florida. Before that, he obtained his Bachelor of Science degree in psychology and minors in business administration and math from Florida Southern College in Lakeland.

He has presented on pharmaceutical litigation and medical device litigation topics in more than 60 panels at attorney conferences all over the country. These include Mass Torts Made Perfect, American Association of Justice, Harris Martin, HB Litigation and Broughton Partners. He has also published several articles on these topics.

Affiliations

  • Florida Bar Association
  • U.S. District Court, Middle District of Florida
  • U.S. District Court, Northern District of Florida

Awards and Certifications

The National Trial Lawyers

  • Top 100 (2023)
  • Top 40 under 40 (2017)

Super Lawyers

  • Rising Star (2016)

Mass Tort Leadership Roles

MDL Co-Lead Counsel

  • In Re: Valsartan, Losartan & Irbesartan Products Liability Litigation


Plaintiffs’ Steering Committee and Chair of Science and Experts

  • In re: Zantac (Ranitidine) Products Liability Litigation

Chair of Discovery Committee:

  • In re: Benicar (Olmesartan) Products Liability Litigation


Chair of Third-Party Committee, Bellwether Committee Member and Discovery Committee Member

  • In re: Bair Hugger Forced Air Warming Products Liability Litigation


Member of Science Committee and Discovery Committee

  • In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation

About Drugwatch’s Experts

Drugwatch’s experts are authorities in their fields. Their personal experiences and professional expertise make them uniquely qualified to review our content for accuracy and verify that the information you read here is trustworthy, comprehensive and consistent with the latest evidence-based research.

More About Our Experts